Novel approaches in small-cell lung cancer
Small-cell lung cancer (SCLC) accounts for approximately 15 % of all lung cancers, and it is associated with poor outcomes . 70 % of these patients present with extensive disease. Their treatment remains a significant challenge for oncologists. The median survival in the extensive disease stage is 7 months to 9 months, and only 2 % of patients survive for 5 years . So far, many attempts to improve upon these results in the first-line setting have failed.